Compare Altria Group Inc (MO) vs Sanofi SA (SNY) Price & Performance

Altria Group (MO) trades at $68.35, up 0.89% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains strong profitability with 39% net income margin and $6.95B net income for 2025, though revenue declined slightly to $20.14B. Recent earnings show alternating beats and misses, with Q3 2026 results pending. Analyst consensus remains bullish with 61.5% buy ratings and $71.50 price target, while the stock offers a 6.3% dividend yield with 56 consecutive annual increases expected.

MO presents value opportunity with 14.4x P/E ratio and strong cash flow generation, but faces headwinds from cigarette volume declines and regulatory pressures. The smoke-free product transition shows progress but remains early stage. Current price near support at $67 suggests limited downside, while analyst targets indicate 4.6% upside potential. Key risks include litigation exposure and slower-than-expected diversification from traditional tobacco products.

SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.

SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.